Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use

Sauvage, M.; Tavitian, Suzanne; Sibaud, V.; Boulinguez, S.; Pages-Laurent, Cécile; Lamant, Laurence; Tournier, É.; Récher, Christian; Meyer, Nicolas

doi:10.1016/j.annder.2020.10.018

Cited by 5 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is only one open‐label, single‐arm, phase II study that is not yet recruiting, designed to test ruxolitinib in organ transplant patients with advanced cSCC (NCT04807777). It is noteworthy that case reports have attributed the development of aggressive cSCC to ruxolitinib use 93–95 …”

Section: Discussionmentioning

confidence: 99%

“…It is noteworthy that case reports have attributed the development of aggressive cSCC to ruxolitinib use. [93][94][95] Ataxia telangiectasia and Rad3-related kinase (ATR) Ataxia telangiectasia and Rad3-related (ATR) kinase is a PI3K-related protein kinase involved in sensing DNA damage during replication and activating DNA repair mechanisms. 96 Inhibition of ATR significantly slows DNA replication.…”

Section: Janus Kinase (Jak)mentioning

confidence: 99%

See 1 more Smart Citation

Molecular and immune targets in cutaneous squamous cell carcinoma

Galambus

Tsai

2022

Molecular Carcinogenesis

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and often confers a good prognosis. Though surgery is the gold standard of treatment, unresectable or metastatic disease can necessitate systemic therapy. Of systemic agents, there is increasing interest in the use of immunotherapies and targeted therapy. Further study into the driver mutations in cSCC has identified opportunities for targeted therapy. In this review, we discuss both current and investigational immune and molecular targets of therapy for cSCC.

show abstract

Section: Discussionmentioning

confidence: 99%